BC Extra | Jan 11, 2020
Company News

Jan. 10 Company Quick Takes: Nektar gains on expanded BMS deal; plus Nurix-Sanofi, Amunix-Roche, Sorrento, Alderaan, Keytruda, Akari, Moderna

BMS, Nektar adding more combo trials to bempeg/Opdivo deal  Bristol-Myers Squibb Co. (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) will start two new registrational trials under an expanded partnership in which they are developing Nektar's bempegaldesleukin (NKTR-214)...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Extra | Nov 11, 2019
Clinical News

Nov. 11 SITC Roundup: Celyad's first clinical data for allogeneic CAR Ts, plus Vaccibody and Nektar

Celyad reports no GvHD, two PRs in allogeneic CAR T trial  Newly presented data from a Phase I trial of an allogeneic CAR T from Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) showed that among 12 patients with...
BC Extra | Sep 26, 2019
Clinical News

Nektar falls on TNBC data for doublet, but considering moving ahead with a triple combo

Despite shedding over $200 million from its market cap Thursday after reporting response data from the triple-negative breast cancer cohort of its bempegaldesleukin/Opdivo nivolumab combination trial, Nektar is looking ahead to the next set of...
BC Extra | Aug 9, 2019
Company News

Nektar links ‘softening’ response to bempegaldesleukin to CMC issues

A year after Nektar reported decreasing responses to its bempegaldesleukin/Opdivo combination, the biotech thinks it has zeroed in on the reason -- manufacturing. However, the pattern isn’t consistent across different tumor types. Shares of Nektar...
BC Extra | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

Nektar gains after FDA breakthrough therapy designation  Nektar Therapeutics Inc. (NASDAQ:NKTR) was up $2.73 (10%) to $31.19 after FDA granted breakthrough designation for bempegaldesleukin (NKTR-214) in combination with Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY)...
BC Extra | Jun 3, 2019
Clinical News

A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo

After going into ASCO with its valuation roughly half what it was before last year’s meeting kicked off, Nektar gained almost $500 million in market cap on Monday after reporting updated data showing that bempegaldesleukin...
BC Innovations | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
BC Week In Review | Mar 1, 2019
Financial News

Syncona leads CHF35M A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round on Feb. 26 to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC)...
BC Extra | Feb 26, 2019
Financial News

Syncona leads CHF35 million A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round Tuesday to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC) is leading...
Items per page:
1 - 10 of 63